Differentiating disseminated cryptococcosis from pulmonary cryptococcosis: roles of clinical characteristics and cryptococcal antigen
- 1Huashan Worldwide Medical Center, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
- 2Institute of Antibiotics, Huashan Hospital, Fudan University, and Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of China, Shanghai, People’s Republic of China
- 3Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
Abstract
Distinguishing disseminated cryptococcosis (DC) from localized pulmonary cryptococcosis (PC) is crucial due to divergent management and disparate prognoses. This study aimed to recognize associated factors for DC from PC in non-human immunodeficiency virus (HIV) patients. Accordingly, 475 pathologically confirmed cryptococcosis cases (391 PC and 84 DC) were retrospectively reviewed over a 20-year period at a tertiary hospital in China. Clinical, radiographic, dynamic serum cryptococcal antigen (CrAg) titer profiles, treatment and prognosis were analyzed. Patients with DC were significantly associated with a history of glucocorticoid therapy (16.7% vs. 5.6%; P = 0.001) and autoimmune diseases (16.7% vs. 6.1%; P = 0.001) compared with PC, aggressive thoracic computed tomography findings, including patchy exudation (P = 0.001) and cavitation (P = 0.009), and markedly higher baseline median serum CrAg titers (1:1280 vs. 1:80, P < 0.001). By multivariable analysis, CNS symptoms (adjusted OR [aOR] 131.12, 95% CI 10.21–1683.9, P = 0.001), chronic liver disease (aOR 15.21, 95% CI 1.06–217.69, P = 0.045), and baseline serum CrAg ≥1:80 (aOR 13.51, 95% CI 1.39–131.07, P = 0.025) remained independently associated with DC. An initial CrAg titer ≥ 1:80 should prompt careful CNS evaluation and consideration of lumbar puncture. Patients with DC had significantly longer median CrAg clearance (P = 0.001) and antifungal duration (18 vs. 6 months), with higher mortality (9.5% vs. 1.0%; P < 0.001) compared to PC. Early risk-stratification is imperative to optimize interventions and improve survival.
Related
- Pulmonary Cryptococcosis Mimicking Lung Metastasis in a Patient with Pancreatic Cancer: A Case Report and Review of the Literature
- Disseminated Pulmonary Coccidioidomycosis Presenting as a Wedge-Shaped Necrotic Mass Mimicking Malignancy
- Disseminated Blastomycosis With Pulmonary, Cutaneous, and Splenic Involvement in a Construction Worker: A Case Report
- Fatal Pulmonary Tumor Thrombotic Microangiopathy Associated With Disseminated Carcinomatosis of the Bone Marrow From Occult Gastric Cancer: An Autopsy-Confirmed Case
- Preoperative fractional exhaled nitric oxide in differentiating pulmonary nodules and pathological examination of non-small cell lung cancer: a retrospective cohort study
BibTeX
@article{zhou2026differentiating,
title = {{Differentiating disseminated cryptococcosis from pulmonary cryptococcosis: roles of clinical characteristics and cryptococcal antigen}},
author = {Xiaolan Zhou and Su Xu and Junhao Zhu and Qiangqiang Zhang and Min Zhu and Minggui Wang},
journal = {Emerging Microbes \& Infections},
year = {2026},
month = oct,
doi = {10.1080/22221751.2026.2751728},
url = {https://doi.org/10.1080/22221751.2026.2751728},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Differentiating disseminated cryptococcosis from pulmonary cryptococcosis: roles of clinical characteristics and cryptococcal antigen
AU - Xiaolan Zhou
AU - Su Xu
AU - Junhao Zhu
AU - Qiangqiang Zhang
AU - Min Zhu
AU - Minggui Wang
PY - 2026
DA - 2026/10/17
JO - Emerging Microbes & Infections
DO - 10.1080/22221751.2026.2751728
UR - https://doi.org/10.1080/22221751.2026.2751728
AB - Distinguishing disseminated cryptococcosis (DC) from localized pulmonary cryptococcosis (PC) is crucial due to divergent management and disparate prognoses. This study aimed to recognize associated factors for DC from PC in non-human immunodeficiency virus (HIV) patients. Accordingly, 475 pathologically confirmed cryptococcosis cases (391 PC and 84 DC) were retrospectively reviewed over a 20-year period at a tertiary hospital in China. Clinical, radiographic, dynamic serum cryptococcal antigen (CrAg) titer profiles, treatment and prognosis were analyzed. Patients with DC were significantly associated with a history of glucocorticoid therapy (16.7% vs. 5.6%; P = 0.001) and autoimmune diseases (16.7% vs. 6.1%; P = 0.001) compared with PC, aggressive thoracic computed tomography findings, including patchy exudation (P = 0.001) and cavitation (P = 0.009), and markedly higher baseline median serum CrAg titers (1:1280 vs. 1:80, P < 0.001). By multivariable analysis, CNS symptoms (adjusted OR [aOR] 131.12, 95% CI 10.21–1683.9, P = 0.001), chronic liver disease (aOR 15.21, 95% CI 1.06–217.69, P = 0.045), and baseline serum CrAg ≥1:80 (aOR 13.51, 95% CI 1.39–131.07, P = 0.025) remained independently associated with DC. An initial CrAg titer ≥ 1:80 should prompt careful CNS evaluation and consideration of lumbar puncture. Patients with DC had significantly longer median CrAg clearance (P = 0.001) and antifungal duration (18 vs. 6 months), with higher mortality (9.5% vs. 1.0%; P < 0.001) compared to PC. Early risk-stratification is imperative to optimize interventions and improve survival.
SN - 2222-1751
ER -